Thread by @edgarvlermamd

Looking forward to #Nephpearls via
#Nephmadness 2️⃣🏀2️⃣🏀
👉🏼 ajkdblog.org/category/nephm…

#NephMadness 2️⃣🏀2️⃣🏀
SGLT2i Region
#Nephpearls
ajkdblog.org/2020/03/13/nep… via @AJKDonline

#NephMadness 2️⃣🏀2️⃣🏀
Vaccines Region
#Nephpearls
ajkdblog.org/2020/03/13/nep… via @AJKDonline

CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM
#VisualAbstract by @brendonneuen
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…

EMPA-REG: Empagliflozin, CV outcomes and mortality in Type 2 Diabetes ca. 2015 from @NEJM
#VisualAbstract by @kidney_boy
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…

CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM
#VisualAbstract by @kidney_boy
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…

CV and Renal Outcomes With Canagliflozin According to Baseline Kidney Function ca. 2018 from @CircAHA
#VisualAbstract by @brendonneuen
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 ahajournals.org/doi/pdf/10.116…

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials ca. 2018 from @TheLancet
#VisualAbstract by @divyaa24
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 ncbi.nlm.nih.gov/m/pubmed/29937…

Kidney Physiology 101: Tubuloglomerular Feedback ca. 2008 from @JASN_News
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 jasn.asnjournals.org/content/jnephr…

Indications for and pharmacologic properties of the aporoved (as of May 2019) SGLT2 inhibitors (SGLT2i) from the August 2019 issue of @KidneyNews
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 asn-online.org/publications/k…

Ongoing Renal and CV Outcome Trials in Type 2 Diabetes from the August 2019 issue of @KidneyNews
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 asn-online.org/publications/k…

Efficacy and Safety of Empagliflozin in Kidney Transplant Recipients With Posttransplant Diabetes Mellitus ca. 2018
#VisualAbstract by @Vernisartan
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 care.diabetesjournals.org/content/early/…

#NephMadness 2️⃣🏀2️⃣🏀
HD Access Region
#Nephpearls
ajkdblog.org/2020/03/13/nep… via @AJKDonline

Patient selection, education and cannulation of percutaneous arteriovenous fistulae (pAVF) being presented by @wasse_m
#VascularAccessPearls #Nephpearls
#Nephmadness 2️⃣🏀2️⃣🏀
👉🏼 cdn.ymaws.com/www.asdin.org/…

Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial in patients with CKD stopped early based on overwhelming efficacy‼️
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 Rationale and protocol academic.oup.com/ndt/article/35…

Dapagliflozin was effective at reducing cardiovascular morbidity and mortality in patients with heart failure and reduced ejection fraction independent of diabetes status ca. 2020 from @JAMA_current
#Nephmadness 2️⃣🏀2️⃣🏀 #Nephpearls
👉🏼 jamanetwork.com/journals/jama/…